drugset
drugset / Trial / NCT05847205

Study Evaluation of Recombinant Hirudin in Prophylaxis of Post-Operative Deep Vein Thrombosis

NCT05847205 ↗

Phase 4 Unknown 100 enrolled MinaPharm Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of r-Hirudin RB variant 15 mg in DVT prophylaxis post major orthopedic operations

Timeline

Start
2022-11-24
Primary completion
2023-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject r-Hirudin Protein / enzyme biologic 15 mg Subcutaneous

Indications

No indication recorded.